{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:30:09Z","timestamp":1793313009657,"version":"4.5.0"},"reference-count":123,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2026,3,24]]},"abstract":"\n Importance<\/jats:title>\n Type 1 diabetes is defined by hyperglycemia due to autoimmune destruction of the insulin-producing beta cells in the pancreas, leading to insulin deficiency, and accounts for 5% to 10% of all cases of diabetes. Type 1 diabetes affects approximately 2 million people in the US and 8.4 million people worldwide and is associated with microvascular and macrovascular complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease.<\/jats:p>\n <\/jats:sec>\n \n Observations<\/jats:title>\n \n Ninety percent to 95% of people with type 1 diabetes have at least 1 autoantibody when they are diagnosed with diabetes. These autoantibodies include autoantibodies to insulin, glutamic acid decarboxylase 65, insulinoma-associated 2, and zinc transporter 8 autoantibodies and are absent in type 2 diabetes or monogenic diabetes (a rarer form of diabetes caused by a single genetic variant). These autoantibodies are present before clinical symptoms develop and can identify early stages of type 1 diabetes. Up to 44% of children and 23% of adults with type 1 diabetes present with diabetes-related ketoacidosis. Type 1 diabetes is most commonly diagnosed between ages 10 and 14 years, but the median age of diagnosis in the US is 24 years. People with type 1 diabetes require lifelong insulin replacement, which can be administered via subcutaneous injection or insulin pump. Insulin regimens that mimic normal physiology include long-acting basal insulin (eg, glargine or degludec) administered once to twice daily and rapid-acting bolus insulin (eg, aspart or lispro) administered prior to meals that contain carbohydrates and during periods of hyperglycemia. Randomized clinical trials have demonstrated that continuous glucose monitors with insulin pumps, which automatically adjust insulin delivery in response to glucose levels, result in less hypoglycemia and improved hemoglobin A\n 1c<\/jats:sub>\n levels (with the greatest improvement occurring in those with higher starting levels [eg, &amp;gt;8.0%]).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Type 1 diabetes accounts for 5% to 10% of all cases of diabetes and is characterized by the presence of islet autoantibodies in 90% to 95% of patients. Lifelong use of insulin therapy is currently required for treatment of type 1 diabetes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jama.2026.0048","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:30:28Z","timestamp":1771259428000},"page":"1070","source":"Crossref","is-referenced-by-count":28,"title":["Type 1 Diabetes"],"prefix":"10.1001","volume":"335","author":[{"given":"Laura M.","family":"Jacobsen","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and Pathology, University of Florida Diabetes Institute, University of Florida College of Medicine, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond A.","family":"Schatz","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics and Pathology, University of Florida Diabetes Institute, University of Florida College of Medicine, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"10","key":"jrv260001r1","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"Global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"jrv260001r3","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.2337\/dc21-0770","article-title":"Adult-onset type 1 diabetes: current understanding and challenges.","volume":"44","author":"Leslie","year":"2021","journal-title":"Diabetes Care"},{"issue":"11","key":"jrv260001r4","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.7326\/M23-1707","article-title":"Age at diagnosis in US adults with type 1 diabetes.","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"key":"jrv260001r5","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.2337\/diabetes.54.suppl_2.S125","article-title":"Environmental triggers and determinants of type 1 diabetes.","volume":"54","author":"Knip","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"jrv260001r6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1111\/apa.16282","article-title":"Seasonality in the manifestation of type 1 diabetes varies according to age at diagnosis in Finnish children.","volume":"111","author":"Turtinen","year":"2022","journal-title":"Acta Paediatr"},{"issue":"2","key":"jrv260001r7","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2337\/dc12-0445","article-title":"Extended family history of type 1 diabetes and phenotype and genotype of newly diagnosed children.","volume":"36","author":"Parkkola","year":"2013","journal-title":"Diabetes Care"},{"issue":"10","key":"jrv260001r8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/S2213-8587(23)00190-0","article-title":"Maternal type 1 diabetes and relative protection against offspring transmission.","volume":"11","author":"Allen","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"jrv260001r9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1028130","article-title":"Biomarkers of autoimmunity and beta cell metabolism in type 1 diabetes.","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"issue":"4","key":"jrv260001r10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/MED.0000000000000548","article-title":"The role of beta-cell dysfunction in early type 1 diabetes.","volume":"27","author":"Sims","year":"2020","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"10","key":"jrv260001r11","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"jrv260001r12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1399-5448.2009.00569.x","article-title":"Diabetic ketoacidosis in children and adolescents with diabetes.","volume":"10","author":"Wolfsdorf","year":"2009","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"jrv260001r13","doi-asserted-by":"publisher","first-page":"648","DOI":"10.2337\/dc24-2483","article-title":"Association of diabetic ketoacidosis at onset, diabetes technology uptake, and clinical outcomes after 1 and 2 years of follow-up: a collaborative analysis of pediatric registries involving 9,269 children with type 1 diabetes from nine countries.","volume":"48","author":"Dovc","year":"2025","journal-title":"Diabetes Care"},{"issue":"6","key":"jrv260001r14","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00125-024-06124-5","article-title":"The INNODIA type 1 diabetes natural history study: a European cohort of newly diagnosed children, adolescents and adults.","volume":"67","author":"Marcovecchio","year":"2024","journal-title":"Diabetologia"},{"issue":"9","key":"jrv260001r15","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dci18-0023","article-title":"Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association.","volume":"41","author":"Chiang","year":"2018","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r16","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.2337\/dc25-S002","article-title":"Diagnosis and classification of diabetes: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"jrv260001r17","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.2337\/dci21-0043","article-title":"The management of type 1 diabetes in adults: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).","volume":"44","author":"Holt","year":"2021","journal-title":"Diabetes Care"},{"issue":"3","key":"jrv260001r18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.7326\/M22-3078","article-title":"Prevalence and management of obesity in US adults with type 1 diabetes.","volume":"176","author":"Fang","year":"2023","journal-title":"Ann Intern Med"},{"issue":"10","key":"jrv260001r19","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.2337\/dbi20-0017","article-title":"Management of latent autoimmune diabetes in adults: a consensus statement from an international expert panel.","volume":"69","author":"Buzzetti","year":"2020","journal-title":"Diabetes"},{"issue":"8","key":"jrv260001r20","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1111\/pedi.13410","article-title":"ISPAD Clinical Practice Consensus Guidelines 2022: stages of type 1 diabetes in children and adolescents.","volume":"23","author":"Besser","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"1","key":"jrv260001r21","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1210\/clinem\/dgae158","article-title":"Lower prevalence of diabetic ketoacidosis at diagnosis in research participants monitored for hyperglycemia.","volume":"110","author":"Sooy","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"jrv260001r22","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1111\/pedi.12151","article-title":"Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up.","volume":"15","author":"Lundgren","year":"2014","journal-title":"Pediatr Diabetes"},{"issue":"8","key":"jrv260001r23","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1111\/pedi.13422","article-title":"Decreased occurrence of ketoacidosis and preservation of beta cell function in relatives screened and monitored for type 1 diabetes in Australia and New Zealand.","volume":"23","author":"Wentworth","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"5","key":"jrv260001r24","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/jamapediatrics.2020.5512","article-title":"Diabetic ketoacidosis at the time of diagnosis of type 1 diabetes in children: insights from TRIGR.","volume":"175","author":"Nakhla","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"2","key":"jrv260001r25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/pedi.12541","article-title":"Ketoacidosis at diagnosis of type 1 diabetes: effect of prospective studies with newborn genetic screening and follow up of risk children.","volume":"19","author":"Hekkala","year":"2018","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"jrv260001r26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1399-5448.2011.00829.x","article-title":"Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies.","volume":"13","author":"Winkler","year":"2012","journal-title":"Pediatr Diabetes"},{"issue":"4","key":"jrv260001r27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/jama.2019.21565","article-title":"Yield of a public health screening of children for islet autoantibodies in Bavaria, Germany.","volume":"323","author":"Ziegler","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"jrv260001r28","doi-asserted-by":"publisher","first-page":"624","DOI":"10.2337\/dc21-0422","article-title":"Heterogeneity of DKA incidence and age-specific clinical characteristics in children diagnosed with type 1 diabetes in the TEDDY study.","volume":"45","author":"Jacobsen","year":"2022","journal-title":"Diabetes Care"},{"issue":"10","key":"jrv260001r29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/S2213-8587(24)00238-9","article-title":"Transitioning to stage 3 type 1 diabetes: when to start insulin.","volume":"12","author":"Besser","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"jrv260001r30","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"jrv260001r31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-058034","article-title":"Comparative efficacy and complications of long-acting and intermediate-acting insulin regimens for adults with type 1 diabetes: an individual patient data network meta-analysis.","volume":"12","author":"Veroniki","year":"2022","journal-title":"BMJ Open"},{"issue":"8","key":"jrv260001r32","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1007\/s11606-021-06642-7","article-title":"Comparative efficacy and safety of ultra-long-acting, long-acting, intermediate-acting, and biosimilar insulins for type 1 diabetes mellitus: a systematic review and network meta-analysis.","volume":"36","author":"Tricco","year":"2021","journal-title":"J Gen Intern Med"},{"issue":"1","key":"jrv260001r33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/dom.13048","article-title":"Glycaemic control and hypoglycaemia during 12?months of randomized treatment with insulin glargine 300?U\/mL versus glargine 100?U\/mL in people with type 1 diabetes (EDITION 4).","volume":"20","author":"Home","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"jrv260001r34","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/dom.14898","article-title":"Continuous glucose monitoring-based time-in-range using insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in type 1 diabetes: the head-to-head randomized controlled InRange trial.","volume":"25","author":"Battelino","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"jrv260001r35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1001\/jama.2017.7115","article-title":"Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial.","volume":"318","author":"Lane","year":"2017","journal-title":"JAMA"},{"issue":"2","key":"jrv260001r36","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1111\/dom.14574","article-title":"Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: the HypoDeg randomized, controlled, open-label, crossover trial.","volume":"24","author":"Pedersen-Bjergaard","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"jrv260001r37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/dom.12588","article-title":"Similar risk of exercise-related hypoglycaemia for insulin degludec to that for insulin glargine in patients with type 1 diabetes: a randomized cross-over trial.","volume":"18","author":"Heise","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"jrv260001r38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/dme.13068","article-title":"Safety and efficacy of insulin degludec\/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1).","volume":"34","author":"Hirsch","year":"2017","journal-title":"Diabet Med"},{"issue":"10","key":"jrv260001r39","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1111\/dom.14100","article-title":"Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: results from the 26-week PRONTO-T1D study.","volume":"22","author":"Klaff","year":"2020","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"jrv260001r40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/dom.14849","article-title":"Efficacy and safety of ultra-rapid lispro versus lispro in children and adolescents with type 1 diabetes: the PRONTO-Peds trial.","volume":"25","author":"Wadwa","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"jrv260001r41","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1089\/dia.2023.0262","article-title":"CamAPS FX hybrid closed-loop with ultra-rapid lispro compared with standard lispro in adults with type 1 diabetes: a double-blind, randomized, crossover study.","volume":"25","author":"Nwokolo","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"7","key":"jrv260001r42","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1111\/dom.14368","article-title":"Improved postprandial glucose control with ultra rapid lispro versus lispro with continuous subcutaneous insulin infusion in type 1 diabetes: PRONTO-Pump-2.","volume":"23","author":"Warren","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"jrv260001r43","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1111\/dom.13545","article-title":"Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial.","volume":"20","author":"Buse","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"jrv260001r44","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/dom.13205","article-title":"Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase III trial.","volume":"20","author":"Mathieu","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"jrv260001r45","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1111\/dom.14355","article-title":"Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomized, crossover study.","volume":"23","author":"Boughton","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"jrv260001r46","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/dia.2023.0178","article-title":"A comparison of faster insulin aspart with standard insulin aspart using hybrid automated insulin delivery system in active children and adolescents with type 1 diabetes: a randomized double-blind crossover trial.","volume":"25","author":"Dovc","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"jrv260001r47","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/dom.13610","article-title":"A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).","volume":"21","author":"Klonoff","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"jrv260001r48","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.2337\/dc24-0838","article-title":"A randomized comparison of postprandial glucose excursion using inhaled insulin versus rapid-acting analog insulin in adults with type 1 diabetes using multiple daily injections of insulin or automated insulin delivery.","volume":"47","author":"Hirsch","year":"2024","journal-title":"Diabetes Care"},{"issue":"9","key":"jrv260001r49","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/dc23-0426","article-title":"Evaluation of insulin pump infusion sites in type 1 diabetes: the DERMIS study.","volume":"46","author":"Kalus","year":"2023","journal-title":"Diabetes Care"},{"issue":"23","key":"jrv260001r50","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1001\/jama.2020.6940","article-title":"Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial.","volume":"323","author":"Laffel","year":"2020","journal-title":"JAMA"},{"key":"jrv260001r51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1503891","article-title":"Impact of the initiation of isCGM soon after type 1 diabetes mellitus diagnosis in adults on glycemic indices and fear of hypoglycemia: a randomized controlled trial.","volume":"15","author":"Hohendorff","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"jrv260001r52","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1089\/dia.2023.0292","article-title":"Effects of 12-week Freestyle Libre 2.0 in children with type 1 diabetes and elevated HbA1c: a multicenter randomized controlled trial.","volume":"25","author":"Jefferies","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"jrv260001r53","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110147","article-title":"Prevention of hypoglycemia by intermittent-scanning continuous glucose monitoring device combined with structured education in patients with type 1 diabetes mellitus: a randomized, crossover trial.","volume":"195","author":"ISCHIA Study Group","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"jrv260001r54","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1111\/pedi.13331","article-title":"The effect of do-it-yourself real-time continuous glucose monitoring on psychological and glycemic variables in children with type 1 diabetes: a randomized crossover trial.","volume":"23","author":"Elbalshy","year":"2022","journal-title":"Pediatr Diabetes"},{"issue":"11","key":"jrv260001r55","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.2337\/dc20-0112","article-title":"Real-time CGM Is superior to flash glucose monitoring for glucose control in type 1 diabetes: the CORRIDA randomized controlled trial.","volume":"43","author":"H\u00e1skov\u00e1","year":"2020","journal-title":"Diabetes Care"},{"issue":"23","key":"jrv260001r56","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1001\/jama.2020.6928","article-title":"Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: a randomized clinical trial.","volume":"323","author":"Pratley","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"jrv260001r57","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1089\/dia.2017.0363","article-title":"A randomized clinical trial of the effect of continuous glucose monitoring on nocturnal hypoglycemia, daytime hypoglycemia, glycemic variability, and hypoglycemia confidence in persons with type 1 diabetes treated with multiple daily insulin injections (GOLD-3).","volume":"20","author":"\u00d3lafsd\u00f3ttir","year":"2018","journal-title":"Diabetes Technol Ther"},{"issue":"3","key":"jrv260001r58","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00125-017-4527-5","article-title":"Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.","volume":"61","author":"Oskarsson","year":"2018","journal-title":"Diabetologia"},{"issue":"10","key":"jrv260001r59","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/dia.2022.0200","article-title":"A multicenter randomized trial evaluating the insulin-only configuration of the bionic pancreas in adults with type 1 diabetes.","volume":"24","author":"Kruger","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"jrv260001r60","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1089\/dia.2022.0201.pub","article-title":"Positive impact of the bionic pancreas on diabetes control in youth 6-17 years old with type 1 diabetes: a multicenter randomized trial.","volume":"24","author":"Messer","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"1","key":"jrv260001r61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/dia.2022.0421","article-title":"Improved glycemia with hybrid closed-loop versus continuous subcutaneous insulin infusion therapy: results from a randomized controlled trial.","volume":"25","author":"Garg","year":"2023","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"jrv260001r62","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1089\/dia.2022.0167","article-title":"A multicenter randomized trial evaluating fast-acting insulin aspart in the bionic pancreas in adults with type 1 diabetes.","volume":"24","author":"Beck","year":"2022","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"jrv260001r63","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1016\/S2589-7500(22)00020-6","article-title":"Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial.","volume":"4","author":"Ware","year":"2022","journal-title":"Lancet Digit Health"},{"issue":"10","key":"jrv260001r64","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1210\/jc.2017-00556","article-title":"Overnight closed-loop control improves glycemic control in a multicenter study of adults with type 1 diabetes.","volume":"102","author":"Brown","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"jrv260001r65","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","article-title":"Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes.","volume":"381","author":"Brown","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv260001r66","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.2337\/dc20-0124","article-title":"Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial.","volume":"43","author":"Brown","year":"2020","journal-title":"Diabetes Care"},{"issue":"9","key":"jrv260001r67","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa2004736","article-title":"A randomized trial of closed-loop control in children with type 1 diabetes.","volume":"383","author":"Breton","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"jrv260001r68","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/S2589-7500(19)30218-3","article-title":"Evening and overnight closed-loop control versus 24\/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial.","volume":"2","author":"Kovatchev","year":"2020","journal-title":"Lancet Digit Health"},{"issue":"12","key":"jrv260001r69","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1001\/jamapediatrics.2021.3965","article-title":"Effect of a hybrid closed-loop system on glycemic and psychosocial outcomes in children and adolescents with type 1 diabetes: a randomized clinical trial.","volume":"175","author":"Abraham","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"11","key":"jrv260001r70","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.2337\/dc22-0470","article-title":"Transitioning of people with type 1 diabetes from multiple daily injections and self-monitoring of blood glucose directly to MiniMed 780G advanced hybrid closed-loop system: a two-center, randomized, controlled study.","volume":"45","author":"Matejko","year":"2022","journal-title":"Diabetes Care"},{"issue":"12","key":"jrv260001r71","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/dc23-0685","article-title":"Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial.","volume":"46","author":"Renard","year":"2023","journal-title":"Diabetes Care"},{"issue":"12","key":"jrv260001r72","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.2337\/dc24-1550","article-title":"Efficacy and safety of a tubeless AID system compared with pump therapy with CGM in the treatment of type 1 diabetes in adults with suboptimal glycemia: a randomized, parallel-group clinical trial.","volume":"47","author":"Renard","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r73","doi-asserted-by":"publisher","first-page":"S146","DOI":"10.2337\/dc25-S007","article-title":"Diabetes technology: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r74","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.2337\/dc25-S006","article-title":"Glycemic goals and hypoglycemia: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r75","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.2337\/dc25-S014","article-title":"Children and adolescents: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"8","key":"jrv260001r76","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2337\/dci19-0028","article-title":"Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range.","volume":"42","author":"Battelino","year":"2019","journal-title":"Diabetes Care"},{"issue":"3","key":"jrv260001r77","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1177\/1932296819883032","article-title":"Clinical recommendations for the use of the ambulatory glucose profile in diabetes care.","volume":"14","author":"Kr\u00f6ger","year":"2020","journal-title":"J Diabetes Sci Technol"},{"issue":"7","key":"jrv260001r78","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/S2213-8587(21)00086-3","article-title":"Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC study.","volume":"9","author":"Jacobson","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"jrv260001r79","doi-asserted-by":"publisher","first-page":"S266","DOI":"10.2337\/dc25-S013","article-title":"Older adults: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r80","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/diaspect.27.1.9","article-title":"Management of type 1 diabetes in older adults.","volume":"27","author":"Dhaliwal","year":"2014","journal-title":"Diabetes Spectr"},{"issue":"1","key":"jrv260001r81","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.2337\/dc25-S015","article-title":"Management of diabetes in pregnancy: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"7","key":"jrv260001r82","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2589-7500(24)00092-X","article-title":"Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: a randomised crossover trial in Montreal, Canada.","volume":"6","author":"Cohen","year":"2024","journal-title":"Lancet Digit Health"},{"key":"jrv260001r83","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.878585","article-title":"Effect and safety of adding metformin to insulin therapy in treating adolescents with type 1 diabetes mellitus: an updated meta-analysis of 10 randomized controlled trials.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"21","key":"jrv260001r84","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1001\/jama.2015.16174","article-title":"Effect of metformin added to insulin on glycemic control among overweight\/obese adolescents with type 1 diabetes: a randomized clinical trial.","volume":"314","author":"Libman","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"jrv260001r85","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1210\/clinem\/dgad471","article-title":"Glucagon-like peptide 1 analogues as adjunctive therapy for patients with type 1 diabetes: an updated systematic review and meta-analysis.","volume":"109","author":"Park","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"jrv260001r86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003461","article-title":"Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: a meta-analysis and meta-regression.","volume":"17","author":"Musso","year":"2020","journal-title":"PLoS Med"},{"issue":"7","key":"jrv260001r87","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00592-021-01686-x","article-title":"Sodium-glucose cotransporter 2 inhibitors as an add-on therapy to insulin for type 1 diabetes mellitus: meta-analysis of randomized controlled trials.","volume":"58","author":"Rao","year":"2021","journal-title":"Acta Diabetol"},{"issue":"4","key":"jrv260001r88","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/jdi.13387","article-title":"Sodium-glucose cotransporter inhibitors as add-on therapy in addition to insulin for type 1 diabetes mellitus: a meta-analysis of randomized controlled trials.","volume":"12","author":"Zou","year":"2021","journal-title":"J Diabetes Investig"},{"issue":"4","key":"jrv260001r89","doi-asserted-by":"publisher","first-page":"325","DOI":"10.5603\/EP.a2020.0034","article-title":"Short- and medium-term efficacy of sodium glucose cotransporter 2 (SGLT-2) inhibitors for the treatment of type 1 diabetes: systematic review and meta-analysis.","volume":"71","author":"Huang","year":"2020","journal-title":"Endokrynol Pol"},{"issue":"12","key":"jrv260001r90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2023.108632","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors as an adjunct to insulin in patients with type 1 diabetes assessed by continuous glucose monitoring: a systematic review and meta-analysis.","volume":"37","author":"Li","year":"2023","journal-title":"J Diabetes Complications"},{"issue":"1","key":"jrv260001r91","first-page":"78","article-title":"A randomised trial of the feasibility of a low carbohydrate diet vs standard carbohydrate counting in adults with type 1 diabetes taking body weight into account.","volume":"25","author":"Krebs","year":"2016","journal-title":"Asia Pac J Clin Nutr"},{"issue":"1","key":"jrv260001r92","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2020-001971","article-title":"Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial.","volume":"9","author":"Sterner Isaksson","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"2","key":"jrv260001r93","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/apa.17455","article-title":"Low-carbohydrate diet proved effective and safe for youths with type 1 diabetes: a randomised trial.","volume":"114","author":"Levran","year":"2025","journal-title":"Acta Paediatr"},{"issue":"1","key":"jrv260001r94","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2337\/dc21-0838","article-title":"Impact of a novel diabetes support system on a cohort of individuals with type 1 diabetes treated with multiple daily injections: a multicenter randomized study.","volume":"45","author":"Bisio","year":"2022","journal-title":"Diabetes Care"},{"issue":"4","key":"jrv260001r95","doi-asserted-by":"publisher","first-page":"533","DOI":"10.20945\/2359-3997000000487","article-title":"Effects of resistance training on the glycemic control of people with type 1 diabetes: a systematic review and meta-analysis.","volume":"66","author":"de Abreu de Lima","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"10","key":"jrv260001r96","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1007\/s40279-024-02059-4","article-title":"Effects of HIIT interventions on cardiorespiratory fitness and glycemic parameters in adults with type 1 diabetes: a systematic review and meta-analysis.","volume":"54","author":"Lazic","year":"2024","journal-title":"Sports Med"},{"issue":"10","key":"jrv260001r97","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.2337\/dc24-0898","article-title":"Management of prolonged aerobic exercise in people with type 1 diabetes on automated insulin delivery systems: a randomized controlled study.","volume":"47","author":"Corrado","year":"2024","journal-title":"Diabetes Care"},{"issue":"11","key":"jrv260001r98","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1210\/clinem\/dgaf448","article-title":"Dietary patterns for weight and glycemic management in persons with type 1 diabetes: a meta-analysis of clinical trials.","volume":"110","author":"Igudesman","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"jrv260001r99","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.2337\/dc25-S005","article-title":"Facilitating positive health behaviors and well-being to improve health outcomes: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"10","key":"jrv260001r100","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.jand.2017.03.022","article-title":"Academy of Nutrition and Dietetics nutrition practice guideline for type 1 and type 2 diabetes in adults: systematic review of evidence for medical nutrition therapy effectiveness and recommendations for integration into the nutrition care process.","volume":"117","author":"Franz","year":"2017","journal-title":"J Acad Nutr Diet"},{"issue":"4","key":"jrv260001r102","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S2213-8587(24)00341-3","article-title":"Long-term outcomes of pancreatic islet transplantation alone in type 1 diabetes: a 20-year single-centre study in Italy.","volume":"13","author":"Catarinella","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"jrv260001r103","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/ajt.13667","article-title":"Pancreas.","volume":"16","author":"Kandaswamy","year":"2016","journal-title":"Am J Transplant"},{"issue":"1","key":"jrv260001r104","doi-asserted-by":"publisher","first-page":"S321","DOI":"10.2337\/dc25-S016","article-title":"Diabetes care in the hospital: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r105","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"2","key":"jrv260001r106","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/EJE-18-0515","article-title":"Associated auto-immune disease in type 1 diabetes patients: a systematic review and meta-analysis.","volume":"180","author":"Nederstigt","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"jrv260001r107","doi-asserted-by":"publisher","first-page":"639","DOI":"10.2337\/dc15-2577","article-title":"Type 1 diabetes and polycystic ovary syndrome: systematic review and meta-analysis.","volume":"39","author":"Escobar-Morreale","year":"2016","journal-title":"Diabetes Care"},{"issue":"9","key":"jrv260001r108","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1007\/s00125-009-1450-4","article-title":"Prevalence and 25 year incidence of proliferative retinopathy among Danish type 1 diabetic patients.","volume":"52","author":"Grauslund","year":"2009","journal-title":"Diabetologia"},{"issue":"1","key":"jrv260001r109","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","article-title":"Cardiovascular disease and risk management: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r110","doi-asserted-by":"publisher","first-page":"S239","DOI":"10.2337\/dc25-S011","article-title":"Chronic kidney disease and risk management: standards of care in diabetes\u20142025.","volume":"48","author":"ElSayed","year":"2025","journal-title":"Diabetes Care"},{"issue":"1","key":"jrv260001r111","doi-asserted-by":"publisher","first-page":"S252","DOI":"10.2337\/dc25-S012","article-title":"Retinopathy, neuropathy, and foot care: standards of care in diabetes\u20142025.","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","journal-title":"Diabetes Care"},{"issue":"12","key":"jrv260001r112","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO).","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"issue":"14","key":"jrv260001r113","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199309303291401","article-title":"Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.","volume":"329","author":"Nathan","year":"1993","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv260001r114","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/dc15-1990","article-title":"Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT\/EDIC study 30-year follow-up.","volume":"39","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2016","journal-title":"Diabetes Care"},{"issue":"25","key":"jrv260001r115","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1056\/NEJMoa052187","article-title":"Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.","volume":"353","author":"Nathan","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"jrv260001r116","doi-asserted-by":"publisher","DOI":"10.1111\/dme.14794","article-title":"Weight gain trajectories and obesity rates in intensive and conventional treatments of type 1 diabetes from the DCCT compared with a control population without diabetes.","volume":"39","author":"Carlson","year":"2022","journal-title":"Diabet Med"},{"key":"jrv260001r117","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2023.110580","article-title":"Long-term and recent trends in survival and life expectancy for people with type 1 diabetes in Finland.","volume":"198","author":"Arffman","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"jrv260001r118","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2014.16425","article-title":"Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010.","volume":"313","author":"Livingstone","year":"2015","journal-title":"JAMA"},{"issue":"21","key":"jrv260001r119","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa1408214","article-title":"Glycemic control and excess mortality in type 1 diabetes.","volume":"371","author":"Lind","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv260001r120","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jama.2014.16107","article-title":"Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.","volume":"313","author":"Orchard","year":"2015","journal-title":"JAMA"},{"key":"jrv260001r121","doi-asserted-by":"publisher","DOI":"10.21037\/pm-22-3","article-title":"A narrative review: polycystic ovary syndrome (PCOS) and type 1 diabetes (T1D).","author":"Bernier","year":"2023","journal-title":"Pediatr Med"},{"issue":"5","key":"jrv260001r122","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s40265-023-01847-y","article-title":"Teplizumab: first approval.","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"7","key":"jrv260001r123","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"jrv260001r2","unstructured":"US Centers for Disease Control and Prevention. National Diabetes Statistics Report: Prevalence of diagnosed diabetes. May 15, 2024. Accessed December 27, 2025. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"key":"jrv260001r101","unstructured":"CITR Coordinating Center. CITR Twelfth Allograft Report. Published June 30, 2025. Accessed December 27, 2025. https:\/\/www.citregistry.org\/system\/files\/CITR%2012th%20Allograft%20Report_2025_Final.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2845229\/jama_jacobsen_2026_rv_260001_1773433839.07834.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:00:57Z","timestamp":1774364457000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2845229"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":123,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,3,24]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2026.0048","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}